Boron chemicals in diagnosis and therapeutics

Bhaskar C. Das, Pritam Thapa, Radha Karki, Caroline Schinke, Sasmita Das, Suman Kambhampati, Sushanta K. Banerjee, Peter Van Veldhuizen, Amit K. Verma, Louis M. Weiss, Todd Evans

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

Advances in the field of boron chemistry have expanded the application of boron from material use to medicine. Boron-based drugs represent a new class of molecules that possess several biomedical applications including use as imaging agents for both optical and nuclear imaging as well as therapeutic agents with anticancer, antiviral, antibacterial, antifungal and other disease-specific activities. For example, bortezomib (Velcade®), the only drug in clinical use with boron as an active element, was approved in 2003 as a proteasome inhibitor for the treatment of multiple myeloma and non-Hodgkin's lymphoma. Several other boron-based compounds are in various phases of clinical trials, which illustrates the promise of this approach for medicinal chemists working in the area of boron chemistry. It is expected that in the near future, several boron-containing drugs should become available in the market with better efficacy and potency than existing drugs. This article discusses the current status of the development of boron-based compounds as diagnostic and therapeutic agents in humans.

Original languageEnglish (US)
Pages (from-to)653-676
Number of pages24
JournalFuture Medicinal Chemistry
Volume5
Issue number6
DOIs
StatePublished - Apr 2013

Fingerprint

Boron
Boron Compounds
Pharmaceutical Preparations
Therapeutics
Proteasome Inhibitors
Optical Imaging
Multiple Myeloma
Antineoplastic Agents
Non-Hodgkin's Lymphoma
Antiviral Agents
Medicine
Clinical Trials

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Molecular Medicine

Cite this

Das, B. C., Thapa, P., Karki, R., Schinke, C., Das, S., Kambhampati, S., ... Evans, T. (2013). Boron chemicals in diagnosis and therapeutics. Future Medicinal Chemistry, 5(6), 653-676. https://doi.org/10.4155/fmc.13.38

Boron chemicals in diagnosis and therapeutics. / Das, Bhaskar C.; Thapa, Pritam; Karki, Radha; Schinke, Caroline; Das, Sasmita; Kambhampati, Suman; Banerjee, Sushanta K.; Van Veldhuizen, Peter; Verma, Amit K.; Weiss, Louis M.; Evans, Todd.

In: Future Medicinal Chemistry, Vol. 5, No. 6, 04.2013, p. 653-676.

Research output: Contribution to journalArticle

Das, BC, Thapa, P, Karki, R, Schinke, C, Das, S, Kambhampati, S, Banerjee, SK, Van Veldhuizen, P, Verma, AK, Weiss, LM & Evans, T 2013, 'Boron chemicals in diagnosis and therapeutics', Future Medicinal Chemistry, vol. 5, no. 6, pp. 653-676. https://doi.org/10.4155/fmc.13.38
Das BC, Thapa P, Karki R, Schinke C, Das S, Kambhampati S et al. Boron chemicals in diagnosis and therapeutics. Future Medicinal Chemistry. 2013 Apr;5(6):653-676. https://doi.org/10.4155/fmc.13.38
Das, Bhaskar C. ; Thapa, Pritam ; Karki, Radha ; Schinke, Caroline ; Das, Sasmita ; Kambhampati, Suman ; Banerjee, Sushanta K. ; Van Veldhuizen, Peter ; Verma, Amit K. ; Weiss, Louis M. ; Evans, Todd. / Boron chemicals in diagnosis and therapeutics. In: Future Medicinal Chemistry. 2013 ; Vol. 5, No. 6. pp. 653-676.
@article{2388af83cf3741699aa9ad65acf2bb35,
title = "Boron chemicals in diagnosis and therapeutics",
abstract = "Advances in the field of boron chemistry have expanded the application of boron from material use to medicine. Boron-based drugs represent a new class of molecules that possess several biomedical applications including use as imaging agents for both optical and nuclear imaging as well as therapeutic agents with anticancer, antiviral, antibacterial, antifungal and other disease-specific activities. For example, bortezomib (Velcade{\circledR}), the only drug in clinical use with boron as an active element, was approved in 2003 as a proteasome inhibitor for the treatment of multiple myeloma and non-Hodgkin's lymphoma. Several other boron-based compounds are in various phases of clinical trials, which illustrates the promise of this approach for medicinal chemists working in the area of boron chemistry. It is expected that in the near future, several boron-containing drugs should become available in the market with better efficacy and potency than existing drugs. This article discusses the current status of the development of boron-based compounds as diagnostic and therapeutic agents in humans.",
author = "Das, {Bhaskar C.} and Pritam Thapa and Radha Karki and Caroline Schinke and Sasmita Das and Suman Kambhampati and Banerjee, {Sushanta K.} and {Van Veldhuizen}, Peter and Verma, {Amit K.} and Weiss, {Louis M.} and Todd Evans",
year = "2013",
month = "4",
doi = "10.4155/fmc.13.38",
language = "English (US)",
volume = "5",
pages = "653--676",
journal = "Future Medicinal Chemistry",
issn = "1756-8919",
publisher = "Future Science",
number = "6",

}

TY - JOUR

T1 - Boron chemicals in diagnosis and therapeutics

AU - Das, Bhaskar C.

AU - Thapa, Pritam

AU - Karki, Radha

AU - Schinke, Caroline

AU - Das, Sasmita

AU - Kambhampati, Suman

AU - Banerjee, Sushanta K.

AU - Van Veldhuizen, Peter

AU - Verma, Amit K.

AU - Weiss, Louis M.

AU - Evans, Todd

PY - 2013/4

Y1 - 2013/4

N2 - Advances in the field of boron chemistry have expanded the application of boron from material use to medicine. Boron-based drugs represent a new class of molecules that possess several biomedical applications including use as imaging agents for both optical and nuclear imaging as well as therapeutic agents with anticancer, antiviral, antibacterial, antifungal and other disease-specific activities. For example, bortezomib (Velcade®), the only drug in clinical use with boron as an active element, was approved in 2003 as a proteasome inhibitor for the treatment of multiple myeloma and non-Hodgkin's lymphoma. Several other boron-based compounds are in various phases of clinical trials, which illustrates the promise of this approach for medicinal chemists working in the area of boron chemistry. It is expected that in the near future, several boron-containing drugs should become available in the market with better efficacy and potency than existing drugs. This article discusses the current status of the development of boron-based compounds as diagnostic and therapeutic agents in humans.

AB - Advances in the field of boron chemistry have expanded the application of boron from material use to medicine. Boron-based drugs represent a new class of molecules that possess several biomedical applications including use as imaging agents for both optical and nuclear imaging as well as therapeutic agents with anticancer, antiviral, antibacterial, antifungal and other disease-specific activities. For example, bortezomib (Velcade®), the only drug in clinical use with boron as an active element, was approved in 2003 as a proteasome inhibitor for the treatment of multiple myeloma and non-Hodgkin's lymphoma. Several other boron-based compounds are in various phases of clinical trials, which illustrates the promise of this approach for medicinal chemists working in the area of boron chemistry. It is expected that in the near future, several boron-containing drugs should become available in the market with better efficacy and potency than existing drugs. This article discusses the current status of the development of boron-based compounds as diagnostic and therapeutic agents in humans.

UR - http://www.scopus.com/inward/record.url?scp=84876850505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876850505&partnerID=8YFLogxK

U2 - 10.4155/fmc.13.38

DO - 10.4155/fmc.13.38

M3 - Article

VL - 5

SP - 653

EP - 676

JO - Future Medicinal Chemistry

JF - Future Medicinal Chemistry

SN - 1756-8919

IS - 6

ER -